RIMEGEPANT SULFATE | N212728 | PFIZER INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Pfizer Inc. et al v. MSN Laboratories Private Ltd. et al 1 patentANDA 219435rimegepant sulfate | D. Del. | 2024-05-23 | Active | — |
Pfizer Inc. et al v. Rubicon Research Private Ltd. 1 patentANDA 219440rimegepant sulfate | D. Del. | 2024-05-23 | Active | — |
| D. Del. | 2024-05-23 | Active | — | |
| D. Del. | 2024-05-23 | Terminated 2026-01-16 | — | |
Pfizer Inc. et al v. Changzhou Pharmaceutical Factory 3 patentsANDA 219385rimegepant sulfate | D. Del. | 2024-05-23 | Active | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Ascent Pharmaceuticals Inc FDA-2025-P-0392 · 8 docket documents Ascent Pharmaceuticals Inc filed this suitability petition under Section 505(j)(2)(C) requesting FDA approval to pursue an abbreviated new drug application for rimegepant oral dissolving film 75 mg, changing the dosage form from the reference-listed drug NURTEC ODT (orally disintegrating tablets 75 | Suitability | 2025-02-05 | Partially Denied | Ascent Pharmaceuticals Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$128.71
per ea
Lowest NADAC/Unit
$128.71
per ea
Brand NDCs
1
Generic NDCs
0
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 72618300002NURTEC ODT 75 MG TABLET | $128.71 | EA | Brand | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.